Logo
I

InFocus Capital Partners

5 employees

InFocus Capital Partners provides seed and early round funding to life science companies, specifically within ophthalmology.

Investor insights

Sectors invested in

Therapeutics8
Health Care8
Biotechnology5
Pharmaceutical3
Glaucoma3
Medical3
Uveitis2
Market Research2
Drug delivery2
Eye diseases2
Ophthalmology2
DR2
AMD2
DME2
Biotechnology and Ophthalmology2
Ophthalmic Drug Development2
Retinal Detachment2
Geographic Atrophy2
Medical Device2
Wearables1

Funding rounds participated in

$8.1M sweet spot round size

Most of their 11 investments are in rounds between $3M and $28M

Investor type

Micro VC

Basic info

Industry

venture capital and private equity principals

Date founded

2019

Investments made

R

RE-VANA raised $12M on November 30, 2022

Investors: -, Visionary Venture Fund, Fund NI, Techstart Ventures LLP and InFocus Capital Partners

S

Stuart Therapeutics raised $11M on March 19, 2021

Investors: Wisconsin Alumni Research Foundation and InFocus Capital Partners

O

ONL Therapeutics raised $47M on December 22, 2020

Investors: Bios Partners, 凯泰资本, Grand Angels, - and InFocus Capital Partners

R

RE-VANA raised $3.3M on June 2, 2020

Investors: Visionary Venture Fund, Clarendon Fund Managers, -, Techstart Ventures LLP and InFocus Capital Partners

M

Mojo Vision Inc. raised $51M on April 29, 2020

Investors: Numbase Group, Khosla Ventures, Intellectus Partners, LLC, Helios Capital, Struck Capital and InFocus Capital Partners

G

Galimedix Therapeutics, Inc. raised undisclosed on January 1, 2020

Investors: InFocus Capital Partners

O

ONL Therapeutics raised $3M on August 22, 2019

Investors: Invest Michigan and InFocus Capital Partners

T

Trefoil Therapeutics raised $28M on July 16, 2019

Investors: Correlation Ventures, Bios Partners, -, AJU IB INVESTMENT and InFocus Capital Partners

P

Pr3vent INC raised $1.5M on February 12, 2019

Investors: InFocus Capital Partners

Q

QURA, Inc. raised $1M on July 3, 2018

Investors: Santen Pharmaceutical and InFocus Capital Partners

FAQ